Takeda AD-4833/TOMM40 303

Back to Drug Development Trials
Drug Development Trials

About the trial

A Blinded Long-term Extension Study of the Safety and Efficacy of Pioglitazone (AD-4833 Sustained Release 0.8mg Daily) to Slow the Progression of Cognitive Decline in Participants Who Have Completed the AD-4833/TOMM40_301 Study With a Diagnosis of Mild Cognitive Impairment Due to Alzheimer Disease

View study